pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›POMALIDOMIDE
drug
save

POMALIDOMIDE

Marketedupdated 6mo ago
by Celgene Corp
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • tagApproval16 co-mentions · 8 sources
  • tagSmall Molecule8 co-mentions · 8 sources
  • companyHetero Labs Ltd2 co-mentions · 2 sources

all catalysts(5)

approval · 5
Jan 26, 2022
approval
5y ago
POMALIDOMIDE — FDA approval
POMALIDOMIDE
→
Sep 26, 2024
approval
2y ago
POMALIDOMIDE — FDA approval
POMALIDOMIDE
→
Aug 5, 2025
approval
1y ago
POMALIDOMIDE — FDA approval
POMALIDOMIDE
→
Oct 17, 2025
approval
1y ago
POMALIDOMIDE — FDA approval
POMALIDOMIDE
→
Dec 29, 2025
approval
11mo ago
POMALIDOMIDE — FDA approval
POMALIDOMIDE
→

Trials studying POMALIDOMIDE

  • phase2A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatmentsrecruitingn=123
  • phase1A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myelomarecruitingn=165
  • phase3A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myelomarecruitingn=520
  • phase3A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131not yet recruitingn=300
  • phase3A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)active not recruitingn=260
  • phase2Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myelomarecruitingn=45
  • phase1A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatmentsrecruitingn=317
  • phase1A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myelomaactive not recruitingn=140

Patent cliff

source: FDA Orange Book
first barrier falls
May 14, 2027
175 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (24)

  • Dec 21, 2031patentUS 8828427*PED
  • Dec 21, 2031patentUS 8828427*PED
  • Dec 21, 2031patentUS 8828427*PED
  • Dec 21, 2031patentUS 8828427*PED
  • Jun 21, 2031compositionUS 88284274.6y
  • Jun 21, 2031compositionUS 88284274.6y
  • Jun 21, 2031compositionUS 88284274.6y
  • Jun 21, 2031compositionUS 88284274.6y
  • Nov 19, 2030patentUS 10555939*PED4.0y
  • Nov 19, 2030patentUS 10555939*PED4.0y
  • Nov 19, 2030patentUS 10555939*PED4.0y
  • Nov 19, 2030patentUS 10555939*PED4.0y
  • Nov 19, 2030patentUS 9993467*PED4.0y
  • Nov 19, 2030patentUS 9993467*PED4.0y
  • Nov 19, 2030patentUS 9993467*PED4.0y
  • Nov 19, 2030patentUS 9993467*PED4.0y
  • May 19, 2030formulationUS 105559393.5y
  • May 19, 2030formulationUS 105559393.5y
  • May 19, 2030formulationUS 105559393.5y
  • May 19, 2030formulationUS 105559393.5y
  • May 19, 2030formulationUS 99934673.5y
  • May 19, 2030formulationUS 99934673.5y
  • May 19, 2030formulationUS 99934673.5y
  • May 19, 2030formulationUS 99934673.5y

FDA exclusivities (16)

  • Nov 14, 2027PEDPediatric (6mo bonus)359d
  • Nov 14, 2027PEDPediatric (6mo bonus)359d
  • Nov 14, 2027PEDPediatric (6mo bonus)359d
  • Nov 14, 2027PEDPediatric (6mo bonus)359d
  • May 14, 2027ODE-296Orphan Drug (7y)175d
  • May 14, 2027ODE-297Orphan Drug (7y)175d
  • May 14, 2027ODE-296Orphan Drug (7y)175d
  • May 14, 2027ODE-297Orphan Drug (7y)175d
  • May 14, 2027ODE-296Orphan Drug (7y)175d
  • May 14, 2027ODE-297Orphan Drug (7y)175d
  • May 14, 2027ODE-296Orphan Drug (7y)175d
  • May 14, 2027ODE-297Orphan Drug (7y)175d
  • Aug 30, 2026PCPC
  • Aug 30, 2026PCPC
  • Aug 30, 2026PCPC
  • Aug 30, 2026PCPC

News(1)

  • Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
    Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.
    biopharma_dive · 3mo ago
brand
POMALIDOMIDE
generic
POMALIDOMIDE
indication
Kaposi Sarcoma
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 3h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?